KDL Biotech Peer Comparison

NSE: KOPDRUGS | BSE: 532291

₹2.14

₹-0.11 (-4.89%)

As on 16-Mar-2015IST

Market cap

₹5 Cr

Revenue (TTM)

₹26 Cr

P/E Ratio

P/B Ratio

-0.1

Div. Yield

0 %

Edit

	KDL Biotech	Wockhardt	Rubicon Research	Acutaas Chemicals	Piramal Pharma
Market cap (₹ Cr)	5	36,196	28,240	27,294	28,644
Revenue (₹ Cr)	--	3,564	1,936	1,462	9,205
Net Profit (₹ Cr)	-14.20	414.00	288.22	387.35	-371.81
Net Margin (%)	-6,396.85	11.23	14.79	26.01	-3.93
RoE (%)	--	8.38	29.77	25.18	-3.85
Price to Earnings	--	88.50	97.98	70.67	--
Price-To-Book	-0.05	7.19	21.04	15.82	3.58

Income Statement (₹ Cr)

	KDL Biotech	Wockhardt	Rubicon Research	Acutaas Chemicals	Piramal Pharma
Operating Revenue	26.47	4,350.50	34.80	33.90	--
Total Income	27.22	4,375.84	34.80	34.61	--
Total Expenditure	28.53	2,996.79	25.65	30.42	--
EBITDA	-2.07	1,353.71	9.15	3.48	--
Depreciation	9.13	115.07	2.71	1.05	--
EBIT	-11.20	1,238.64	6.44	2.42	--
Interest	6.77	269.02	2.51	1.10	--
Other Income	0.76	25.34	0.42	0.71	--
Exceptional Items	-11.50	-473.77	--	--	--
Profit before Tax	-17.21	521.19	3.93	2.03	--
Provision for Tax	7.69	221.74	1.40	0.68	--
Profit after Tax	-17.21	299.45	2.52	1.35	--

	KDL Biotech	Wockhardt	Rubicon Research	Acutaas Chemicals	Piramal Pharma
Shareholder's Funds	-59.17	1,471.02	37.49	6.11	--
Minority Interest	--	--	--	--	--
Non-Current Liabilities	2.66	2,891.88	5.39	0.04	--
Current Liabilities	113.21	1,890.94	24.92	15.82	--
Total Liabilities	56.70	6,253.84	67.79	22.09	--

	KDL Biotech	Wockhardt	Rubicon Research	Acutaas Chemicals	Piramal Pharma
Non-Current Assets	49.80	3,772.33	47.64	5.51	--
Current Assets	6.89	2,481.51	20.15	16.45	--
Total Assets	56.70	6,253.84	67.79	22.09	--
Total Debt*	60.26	3,492.50	19.14	6.41	--
Net Current Assets	-106.32	590.57	-4.76	0.63	--
Contingent Liabilities	90.96	46.91	0.71	--	--

	KDL Biotech	Wockhardt	Rubicon Research	Acutaas Chemicals	Piramal Pharma
Cash From Operating Activities	6.79	1,343.83	5.07	--	--
Cash Flow from Investing Activities	0.00	-305.45	-4.60	--	--
Cash from Financing Activities	-6.73	-826.56	-0.83	--	--
Net Cash Inflow / Outflow	0.06	211.82	-0.36	0.00	--

	KDL Biotech	Wockhardt	Rubicon Research	Acutaas Chemicals	Piramal Pharma
ROCE (%)	-108.39	16.20	12.09	25.61	--
ROE (%)	0.00	66.74	14.65	24.87	--
ROA (%)	-28.21	4.97	4.06	6.42	--
EBIT Margin (%)	-4.94	31.70	26.29	12.34	--
Net Margin (%)	-63.22	6.84	7.25	3.90	--
Cash Profit Margin (%)	-29.64	9.52	15.04	6.56	--

	KDL Biotech	Wockhardt	Rubicon Research	Acutaas Chemicals	Piramal Pharma
Revenue Growth (%)	-6.83	15.97	65.29	21.86	--
EBIT Growth (%)	91.84	29.05	42.04	27.63	--
Net Profit Growth (%)	73.24	212.90	6.25	7.55	--
EPS Growth (%)	73.24	278.36	6.25	7.55	--
Book Value Growth (%)	-41.02	253.45	15.81	28.51	--

	KDL Biotech	Wockhardt	Rubicon Research	Acutaas Chemicals	Piramal Pharma
Price / Earnings	0.00	17.64	0.00	0.00	--
Price / Book Value	-0.15	9.37	0.00	0.00	--
Dividend Yield (%)	0.00	0.00	--	--	--
EV/EBITDA	-52.39	7.33	4.36	1.71	--
Market Cap (₹ Cr)	8.80	6,555.46	0.00	0.00	--

	KDL Biotech	Wockhardt	Rubicon Research	Acutaas Chemicals	Piramal Pharma
Debt to Equity	-1.02	2.39	0.51	1.05	--
Short term debt to equity ratio	-0.87	0.18	0.21	0.88	--
Current Ratio	0.06	1.31	0.81	1.04	--
Quick Ratio	0.04	0.84	0.77	0.66	--
Interest Coverage	-1.54	2.94	2.57	2.86	--

	KDL Biotech	Wockhardt	Rubicon Research	Acutaas Chemicals	Piramal Pharma
Debtors to sales (%)	0.06	17.44	42.51	24.27	--
Asset Turnover	0.45	0.72	0.56	1.74	--
Receivable days	2.08	57.17	120.33	81.45	--
Inventory Days	34.92	67.16	9.04	45.36	--
Payable days	425.93	116.25	535.25	134.63	--
Cash Conversion Cycle	-388.93	8.07	-393.94	-7.82	--

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.